Fig. 2

CEBPD contributes to self-renewal in U373MG and T98G spheroid cells under IL-1β treatment. a Western blot analyses conducted with indicated antibodies using protein lysates from U373MG or T98G spheroid cells stably expressing shLacZ or shC7 treated with or without 5 ng/mL IL-1β on day 3 and 6. Expression of α-tubulin served as the internal control. b Images collected from tumor spheroids of U373MG or T98G cells stably expressing shLacZ or shC7 treated with or without 5 ng/mL IL-1β. Scale bar, 0.5 mm. c, d Quantitative analysis results of tumor spheroid area and number in b using ImageJ software. Cells transduced with shLacZ served as the sham control. (Total data were obtained from three independent experiments, and the data shown here were from one representative assay. All data are expressed as mean ± SEM. Differences among groups were determined with one-way ANOVA followed by Tukey’s multiple comparison test. *p < 0.05, **p < 0.01, ***p < 0.001) shLacZ, shβ-galactosidase; shC7, shCEBPD